A potential treatment for breast cancer, lung cancer, chronic lymphocytic leukemia, and glioblastoma may also work against prostate cancer. Imetelstat—already in clinical trials for some cancers—blocks telomerase, an enzyme that eliminates cancer cells’ cues to stop dividing.
As Jerry W. Shay, PhD, and coinvestigators explain in the International Journal of Cancer (2010; published online ahead of print), almost all cancer therapies target the bulk tumor cells, but may leave intact a small population of tumor-initiating cells, which are believed to be responsible for relapse and metastasis.
Investigators found significant telomerase activity in tumor-intiating cells taken from human prostate cancer cells. Imetelstat inhibited the enzyme, providing new opportunities for combination therapies.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.